The Science Behind the Coronavirus, Series III: Mutations
In the third installment of the Los Angeles Times series “The Science Behind the Coronavirus,” Dr. Patrick Soon-Shiong, the executive chairman of the Times, examines the pandemic’s latest threat: a second wave of global infections fueled by mutations to the virus. The multiple mutations resulting in these variants, Dr. Soon-Shiong explains, raise critical questions about the effectiveness of monoclonal antibodies, convalescent plasma and even antibody-based vaccines which have been designed to block the first wave of SARS-CoV-2.
Joining Dr. Soon-Shiong is Professor Tulio de Oliveira, a Brazilian-South African geneticist and bioinformatician who, along with a team of scientists, made the seminal discovery of the multiple mutations that gave rise to a contagious new variant in South Africa.
Dr. Patrick Soon-Shiong is a surgeon and scientist who has spent his career studying the human immune system to fight cancer and infectious disease. In mid-October, Soon-Shiong's company, ImmunityBio, received permission from the Food and Drug Administration to begin Phase 1 trials of its COVID-19 vaccine candidate. He has also received approval to begin trials in South Africa, where he will explore the potential of his T cell vaccine to prevent infection from these mutated virus strains.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
Видео The Science Behind the Coronavirus, Series III: Mutations канала Los Angeles Times
Joining Dr. Soon-Shiong is Professor Tulio de Oliveira, a Brazilian-South African geneticist and bioinformatician who, along with a team of scientists, made the seminal discovery of the multiple mutations that gave rise to a contagious new variant in South Africa.
Dr. Patrick Soon-Shiong is a surgeon and scientist who has spent his career studying the human immune system to fight cancer and infectious disease. In mid-October, Soon-Shiong's company, ImmunityBio, received permission from the Food and Drug Administration to begin Phase 1 trials of its COVID-19 vaccine candidate. He has also received approval to begin trials in South Africa, where he will explore the potential of his T cell vaccine to prevent infection from these mutated virus strains.
SUBSCRIBE FOR MORE VIDEOS AND NEWS
http://www.youtube.com/subscription_center?add_user=losangelestimes
https://www.latimes.com/subscription
LET’S CONNECT:
Facebook ► https://www.facebook.com/latimes
Twitter ► https://twitter.com/LATimes
Instagram ► https://www.instagram.com/latimes
Видео The Science Behind the Coronavirus, Series III: Mutations канала Los Angeles Times
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
‘Second Opinion,’ Episode 4: The Long-HaulersDr. Patrick Soon-Shiong Says 'Triangle Offense' Against Cancer Is WorkingThe Science Behind the Coronavirus, Series ICOVID 19 Vaccine Deep Dive: Safety, Immunity, RNA Production, (Pfizer Vaccine / Moderna Vaccine)You Will Love This Vaccine (Novavax Vaccine)NEW COVID 19 Variants (How Concerned Should We BE?) | COVID Update TodayThe Science Behind the Coronavirus, Series IV: Variants and VaccinesJesse Bloom: "Interpreting the Evolution of SARS-CoV-2"Master's Commencement Speaker: Patrick Soon ShiongThe Science Behind the Coronavirus, Series IINantKwest's Soon-Shiong on BioTech and the Future of NewspapersDr. Pat Soon-Shiong: Cytokine or Cytopathic Storm?The Insane Biology of: The OctopusAre African countries staying ahead of the coronavirus? I Inside StorySadhguru and Deepak Chopra Predict The Future After Vaccine | Holistic Health | MOIGenomic Analysis of SARS-COV-2: New Variants and the Vaccine (Webinar)NantKwest's Patrick Soon-Shiong on reverse merger with ImmunityBioThe Science Behind How the Coronavirus Affects the Brain | WSJNETEC: SARS-CoV-2: Mutations and Variants and Strains (oh my!)Chapter 3: Will antibodies block this next wave of variants?